[HTML][HTML] Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD–mixed treatment comparisons of clinical efficacy

G Stynes, H Svedsater, J Wex, S Lettis, D Leather… - Respiratory …, 2015 - Springer
Background Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily inhaled
corticosteroid (ICS)/long-acting beta 2 agonist (LABA) treatment approved in the United …

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD-mixed treatment comparisons of clinical efficacy

G Stynes, H Svedsater, J Wex, S Lettis… - Respiratory …, 2015 - hero.epa.gov
Background: Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily inhaled
corticosteroid (ICS)/long-acting beta (2) agonist (LABA) treatment approved in the United …

[PDF][PDF] Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD–mixed treatment comparisons of clinical efficacy

G Stynes, H Svedsater, J Wex, S Lettis, D Leather… - 2015 - core.ac.uk
Abstract Background: Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily
inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment approved in the …

[HTML][HTML] Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD–mixed treatment comparisons of clinical efficacy

G Stynes, H Svedsater, J Wex, S Lettis… - Respiratory …, 2015 - ncbi.nlm.nih.gov
Background Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily inhaled
corticosteroid (ICS)/long-acting beta 2 agonist (LABA) treatment approved in the United …

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD-mixed treatment comparisons of clinical efficacy

G Stynes, H Svedsater, J Wex, S Lettis… - Respiratory …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily inhaled
corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment approved in the United …

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD–mixed treatment comparisons of clinical efficacy

G Stynes, H Svedsater, J Wex, S Lettis, D Leather… - Respiratory …, 2015 - infona.pl
Background Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily inhaled
corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment approved in the United …

[PDF][PDF] Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD–mixed treatment comparisons of clinical efficacy

G Stynes, H Svedsater, J Wex, S Lettis, D Leather… - 2015 - researchgate.net
Abstract Background: Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily
inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment approved in the …

[HTML][HTML] Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD–mixed treatment comparisons of clinical efficacy

G Stynes, H Svedsater, J Wex… - Respiratory …, 2015 - respiratory-research.biomedcentral …
Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily inhaled corticosteroid
(ICS)/long-acting beta2 agonist (LABA) treatment approved in the United States, Canada …

[PDF][PDF] Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD–mixed treatment comparisons of clinical efficacy

G Stynes, H Svedsater, J Wex, S Lettis, D Leather… - 2015 - cyberleninka.org
Abstract Background: Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily
inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment approved in the …

[PDF][PDF] Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD–mixed treatment comparisons of clinical efficacy

G Stynes, H Svedsater, J Wex, S Lettis, D Leather… - 2015 - academia.edu
Abstract Background: Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily
inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment approved in the …